

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2004205617 B2

(54)	Title Novel compounds		
(51)	International Patent Classification(s) C07D 495/04 (2006.01)		
(21)	Application No:	2004205617	(22) Date of Filing: 2004.01.15
(87)	WIPO No: WO04/065393		
(30)	Priority Data		
(31)	Number 0300120-3	(32) Date 2003.01.17	(33) Country SE
(43)	Publication Date:	2004.08.05	
(44)	Accepted Journal Date:	2007.03.08	
(71)	Applicant(s) AstraZeneca AB		
(72)	Inventor(s) Rasul, Rukhsana Tasneem;Cooper, Martin Edward;Ingall, Anthony Howard;Guile, Simon David		
(74)	Agent / Attorney Freehills Patent & Trade Mark Attorneys, GPO Box 128, Melbourne, VIC, 3000		
(56)	Related Art WO 1999/029695		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/065393 A1

(51) International Patent Classification⁷: **C07D 495/04**,
A61K 31/50

(21) International Application Number:
PCT/SE2004/000051

(22) International Filing Date: 15 January 2004 (15.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0300120-3 17 January 2003 (17.01.2003) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COOPER, Martin, Edward** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). **GUILE, Simon, David** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). **INGALL, Anthony, Howard** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB). **RASUL, Rukhsana, Tasneem** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leics. LE11 5RH (GB).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IIU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IIU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS



(57) Abstract: The invention relates to thienopyridazinones of formula (I): wherein: R¹ is C₁₋₆ alkyl, C₂₋₆ alkenyl or C₃₋₆ cycloalkyl which is optionally substituted by C₁₋₆ alkyl, each of the above being optionally substituted by one or more halogen atoms; R² is C₁₋₆ alkyl; R³ is a group CO-G or SO₂-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C₁₋₄ alkyl; Q is CR⁵R⁶ where R⁵ and R⁶ are as defined in the specification; and R⁴ is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted as described in the specification, and pharmaceutically acceptable salts and solvates thereof. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular in the modulation of autoimmune disease are also described.


WO 2004/065393 A1

NOVEL COMPOUNDS

The present invention relates to thienopyridazinones, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The invention 5 also relates to their use in the modulation of autoimmune disease.

T-cells play an important role in the immune response, however in auto-immune disease T-cells are inappropriately activated against particular tissues and proliferate, eg causing the inflammation associated with rheumatoid arthritis. Inhibition of the proliferation of 10 T-cells is beneficial in the modulation of autoimmune disease. The present invention relates to compounds which are beneficial in the modulation of autoimmune disease.

In accordance with the present invention, there is provided a compound of formula (1):



15

(1)

wherein:

R¹ is C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkyl-C₃₋₆ cycloalkyl or C₃₋₆ cycloalkyl which is 20 optionally substituted by C₁₋₆ alkyl, each of these R¹ above being optionally substituted by one or more halogen atoms;

R² is C₁₋₆ alkyl;

R³ is a group CO-G or SO₂-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C₁₋₄ alkyl;

Q is CR⁵R⁶ where R⁵ is hydrogen, C₁₋₆ alkyl or fluorine and R⁶ is hydrogen, OH or fluorine, or R⁵ and R⁶ together form a = O group, with the proviso that R⁵ cannot be fluorine when R⁶ is OH;

5 R⁴ is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by up to 4 groups independently selected from halogen, C₁₋₄ alkyl, (poly)halo-C₁₋₄-alkyl, C₁₋₄ alkoxy, (poly)halo-C₁₋₄-alkoxy, C₁₋₄ alkylsulphonyl, (poly)halo- C₁₋₄-alkylsulphonyl, oxo, thioxo, cyano, hydroxymethyl, methylthio, -

10 NR⁷R⁸, -CO-NR⁷R⁸, -SO₂.NR⁷R⁸, or a 5- to 6-membered aromatic ring system wherein up to 3 ring atoms may be heteroatoms independently selected from oxygen, sulphur and nitrogen, and which may itself be substituted by up to 4 groups selected from halogen, C₁₋₄ alkyl, (poly)halo-C₁₋₄-alkyl, C₁₋₄ alkoxy, (poly)halo-C₁₋₄-alkoxy, C₁₋₄ alkylsulphonyl, (poly)halo- C₁₋₄-alkylsulphonyl, oxo, thioxo, cyano, hydroxymethyl,

15 methylthio, -NR⁷R⁸, -CO-NR⁷R⁸, -SO₂-NR⁷R⁸;

R⁷ and R⁸ are independently hydrogen, C₁₋₄ alkyl; or R⁷ and R⁸ together with the nitrogen atom to which they are attached may form a 5 to 7 membered saturated heterocyclic ring,

20

and pharmaceutically acceptable salts and solvates thereof.

Preferably R¹ is C₁₋₆ alkyl or C₃₋₆ cycloalkyl. For instance, R¹ is selected from ethyl, isobutyl, isopropyl or cyclopropyl. More preferably R¹ is isobutyl, isopropyl or cyclopropyl.

Suitably R² is C₁₋₃ alkyl, such as methyl or ethyl. Preferably R² is methyl.

Suitably G in group R³ is a 5-membered ring containing an oxygen atom, such as an isoxazolidinyl ring. Preferably the ring G is substituted by a single hydroxy substituent. A hydroxyl substituent may not be attached to a ring carbon atom that is bonded to a ring heteroatom. The group G is preferably linked to the CO or SO₂ group through its

ring nitrogen atom. Particular examples of the group G are is 4-hydroxy-isoxazolidin-2-yl or 4-hydroxy-4-methyl-isoxazolidin-2-yl.

Preferably R³ is a group CO-G as defined above in which the ring G is linked via a 5 nitrogen atom. More preferably R³ is a group CO-G where G is a 5-membered ring as described above.

Most preferably R³ is 4-hydroxy-isoxazolidin-2-ylcarbonyl or 4-hydroxy-4-methyl-isoxazolidin-2-yl carbonyl.

10

Suitably Q is CR⁵R⁶ where R⁵ is hydrogen, C₁₋₆ alkyl and R⁶ is hydrogen. Preferably Q is CH₂.

15

Examples of 5-10 membered mono- or bi-cyclic aromatic ring systems for R⁴ include thienyl, furanyl, pyrrolyl, pyrrolopyridino, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl and quinolyl.

20

Where R⁴ is a bicyclic aromatic ring system, a particular example is pyrrolopyridino

25


Preferably R⁴ is a 5-membered aromatic ring containing two heteroatoms optionally substituted as defined above. A particular example of R⁴ is an optionally substituted pyrazole ring. Preferably R⁴ is a substituted pyrazole ring

30

Suitable substituents are those listed above, but in particular are selected from C₁₋₆alkyl, or haloC₁₋₆alkyl or a 5- to 6-membered aromatic ring system wherein up to 3 ring atoms may be heteroatoms independently selected from oxygen, sulphur and nitrogen.

30

For instance, R^4 is suitably a group of sub-formula (i)



(i)

where R¹⁰ and R¹¹ are independently selected from H, C₁₋₆alkyl, or haloC₁₋₆alkyl

5 and R¹² is selected from H, C₁₋₆alkyl, or haloC₁₋₆alkyl or a 5- to 6-membered aromatic ring system wherein up to 3 ring atoms may be heteroatoms independently selected from oxygen, sulphur and nitrogen.

In R¹⁰ and R¹¹ are selected from H or C₁₋₃alkyl, such as methyl.

10 In particular, both R¹⁰ and R¹¹ is C₁₋₃alkyl such as methyl.

Suitably R¹² is selected from H, C₁₋₃alkyl (such as methyl) or a 5- to 6-membered aromatic ring system wherein up to 3 ring atoms may be heteroatoms independently selected from oxygen, sulphur and nitrogen. Where R¹² is a 5- to 6- membered aromatic ring system, particular examples of such systems are pyridyl (such as 2-pyridyl), 15 pyrimidinyl (such as 2-pyrimidinyl) or thiazolyl (such as 2-thiazolyl).

Preferably R¹² is H.

20 In an embodiment of the invention R⁴ is a pyrazole ring, substituted by alkyl such as C₁₋₆alkyl, or haloC₁₋₆alkyl such as or trifluoromethyl substituents and/or also substituted by a 2-pyrimidinyl or 2-pyridyl group.

25 Where R⁷ and R⁸ form a 5 to 7 membered saturated heterocyclic ring examples of suitable rings include morpholine, piperidine, piperazine and pyrrolidine.

Preferred compounds of formula (I) include:

2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-2-isoxazolidinyl]carbonyl- 5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one,

2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-2-isoxazolidinyl]carbonyl]- 5-methyl-7-(2-methylpropyl)thieno[2,3-*d*]pyridazin-4(*5H*)-one,

2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[[*(4S)*-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-5-ethyl-3-[[*(4S)*-4-hydroxy-2-isoxazolidinyl]carbonyl]-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one,

2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-thieno[2,3,-*d*]pyridazin-4(*5H*)-one,

2-[(3,5-Dimethyl-1*H*-pyrazol-40yl)methyl]-7-ethyl-3-[[*(4S)*-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

3-[[*(4S)*-4-hydroxyisoxazolidinyl]carbonyl-5-methyl-7-(2-methylpropyl)-2-(1*H*-pyrrolo[2,3-*b*]pyridine-3-ylmethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one,

3-[[*(4S)*-4-Hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-2-[(1,3,5-trimethylpyrazol-4-yl)methyl]-thieno[2,3,-*d*]pyridazin-4(*5H*)-one,

2-[[3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-3-[[*(4S)*-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

2-[[3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-3-[[*(4S)*-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,

7-Ethyl-3-[(4S)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl}-5-methyl-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one,
2-[(3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one,
5 2-[(3,5-Dimethyl-1-(2-pyrimidinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one,
2-[(3,5-Dimethyl-1-(2-thiazolyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one
10 and pharmaceutically acceptable salts thereof.

Alkyl groups, whether alone or as part of another group, can be straight chained or branched. Unless otherwise specified, they will generally comprise from 1 to 6 and
15 suitably from 1 to 4 carbon atoms.

Examples of (poly)haloC₁₋₄alkyl groups include haloC₁₋₄alkyl groups such as chloro- or fluoromethyl, as well as dihaloC₁₋₄alkyl groups such as difluoro- or dichloromethyl and trihaloC₁₋₄alkyl groups such as trifluoromethyl.

20 It will be understood that a compound of the formula I or a salt thereof may exhibit the phenomenon of tautomerism and that the drawings within this specification represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form.

25 Certain compounds of formula (1) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (1) and mixtures thereof including racemates. These also form an aspect of the present invention.

30 Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I and their


pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula I as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording 5 pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, 10 fumarates, succinates, lactates and tartrates. In addition where the compounds of formula I are sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium 15 salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

Preferred salts include an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulfonate or *p*-toluenesulfonate, or an alkali metal salt such as a sodium or potassium salt. 20

In a further aspect the invention provides a process for the preparation of a compound of formula (I) which comprises:

25 (a) for compounds of formula (I) where R^3 is COG:

reaction of a compound of formula (II):



(II)

5 in which R^1 , R^2 , R^4 and Q are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (III):




10 where G is as defined in formula (I) in the presence of a coupling agent, or

(b) for compounds of formula (I) where R^3 is SO_2-G :

reacting a compound of formula (IV):

15



(IV)

20 in which in which R^1 , R^2 , R^4 and Q are as defined in formula (II) and L and L' are leaving groups with a compound of formula (III) as defined above, and optionally thereafter process (a) or (b) in any order


- removing any protecting groups
- forming a pharmaceutically acceptable salt.

When the compound of formula (III) is an nitrogen atom bonded to the H group, a preferred compound of formula (II) has hydroxy as the leaving group L, so that the reaction can be effected using amide coupling. Reaction of compounds (II) and (III) is 5 suitable carried out in the presence of a coupling agent such as diethyl chlorophosphate and N-hydroxybenzotriazole and a base such as an organic amine, for example triethylamine. The reaction is carried out in a suitable solvent such as dichloromethane or acetonitrile at a temperature of about 0°C to about 35°C, preferably at about 15°C to about 25°C.

10

Suitable leaving groups L and L' include halo groups such as fluoro, chloro or bromo or in the case of the compound of formula (IV), it may be an anhydride group such as a sulphonic acid anhydride or acetyl anhydride.

15 Compounds of formula (II) can be prepared by reacting a compound of formula (V):




(V)

20

in which R¹, R², R⁴ and Q are as defined in formula (II), and R¹³ is a halo group such as bromo or iodo, and preferably bromo, with a suitable Grignard reagent followed by treatment with carbon dioxide. The reaction is preferably carried out using a hindered Grignard reagent such as isopropyl magnesium chloride in a solvent such as THF at 25 reduced temperature, for example at about 0°C to about 25°C, preferably at about 0°C to about 5°C with the carbon dioxide quench carried out at from about 0°C to about 25°C.

Compounds of formula (V) where Q is CHR^5 can be prepared by reacting a compound of formula (VI):




5

(VI)

in which R¹, R², R⁴ and Q are as defined in formula (II), and R¹³ is as defined in relation to formula (V), with a strong acid such as trifluoroacetic acid in the presence of a 10 hydride source such as triethylsilane. The reaction is carried out optionally in the presence of a halocarbon solvent such as dichloromethane at a temperature of about 0°C to about 35°C, preferably at about 15°C to about 25°C.

Compounds of formula (VI) can be prepared by reacting a compound of formula (VII):

15




(VII)

20 in which R¹ and R² are as defined in formula (II) and R¹³ is as defined in relation to formula (V), with a lithium alkylamide such as lithium diisopropylamide in an aprotic solvent such as THF. The reaction is carried out at a temperature of between about -10°C and about 25°C, preferably at about 0°C to about 5°C, followed by treatment with a compound of formula (VIII):


25

11



where R^4 and R^5 are as defined in formula (I) or are protected derivatives thereof, at a temperature of between about 0°C and about 50°C, preferably at about 10°C to about 5 30°C.

Compounds of formula (VII) can be prepared by treating a compound of formula (IX):




10

(IX)

in which R^1 and R^2 are as defined in formula (II) with a halogenating agent such as bromine, in an inert solvent such as aqueous acetic acid at a temperature of between 15 about 20°C and about 100°C, preferably at about 50°C to about 100°C.

Compounds of formula (IX) can be prepared by reaction of a compound of formula (X):




20

(X)

in which R^1 is as defined in formula (II) with a compound of formula (XI):


25



in which R^2 is as defined in formula (II). The reaction can be carried out in a polar solvent such as ethanol at a temperature of about 20°C to about 125°C, preferably at about 50°C to about 100°C.

5


Compounds of formula (X) can be prepared by treating thiophene-3-carboxylic acid with a base, preferably a lithium alkylamide such as lithium diisopropylamide. The reaction is carried out in an aprotic solvent such as THF at a temperature of about -78°C to about 25°C, preferably at about -50°C to about 10°C. The anion is treated with a compound of 10 formula (XII):



in which R^1 is as defined in formula (II) and L'' is a leaving group such as O,N-dimethyl hydroxylamino, at a temperature of about 0°C to about 50°C, preferably at about 10°C to about 30°C.

Compounds of formula (IV) can be prepared from compounds of formula (V) by treating with a Grignard reagent as defined above and quenching with sulphur dioxide at a 20 temperature of about -50°C to about 100°C, followed by oxidation of the resulting intermediate and chlorination, for example with phosphorous pentachloride.


Compounds of formula (V) where Q is CF_2 , that is a compound of formula (XIII):



25

(XIII)

in which R¹, R² and R⁴ are as defined in formula (II) and R¹³ is as defined in relation to formula (V), can be prepared from a compound of formula (XIV):



5

(XIV)


in which R¹, R² and R⁴ are as defined in formula (II) and R¹³ is as defined in relation to formula (V), by treating with a fluorinating agent such as diethylamino sulphur 10 trifluoride in an inert solvent such as dichloromethane at a temperature from about -30°C to about 50°C.

Compounds of formula (XIV) are prepared from compounds of formula (VI) as defined above where R⁵ is hydrogen using an oxidant such as tetrapropylammonium 15 perruthenate in the presence of N-methyl morpholine N-oxide in a solvent such as dichloromethane at a temperature of about -20°C to about 50°C.

Starting materials as defined above are available commercially or can be prepared using routine chemistry known in the art.

20

Alternatively or additionally, compounds of formula (I) can be converted to different compounds of formula (I) using conventional chemical methods. For instance, compounds of formula (I) where R⁴ is a group of sub-formula (i) above, wherein R¹² is hydrogen can be converted to compounds of formula (i) where R¹² is other than 25 hydrogen by reaction with a compound of formula (XV)



where $R^{12'}$ is a group R^{12} other than hydrogen, and L'' is a leaving group such as halo, and in particular bromo. Such a reaction may be carried out in an organic solvent such as acetonitrile or dioxan. If necessary the reaction can be carried out in the presence of a base such as an alkali metal carbonate, for instance potassium carbonate, and in the 5 presence of a catalyst such as a copper salt like copper iodide. Also if necessary, the reaction can be effected under an inert atmosphere such as nitrogen.

Other reactions, in particular for the conversion of one group R^3 of R^4 to different such groups would be apparent to a skilled chemist.

10

The compounds of the invention are useful because they possess pharmacological activity in human and non-human animals. They are indicated as pharmaceuticals for use in the (prophylactic) treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunologically mediated diseases including rejection 15 of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).

Examples of these conditions are:

- (1) **(the respiratory tract)** airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust 20 asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis 25 including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's 30 disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus,

Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;

5 (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;

10 (5) **(other tissues and systemic disease)** multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura;

15 (6) **(allograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease; and

(7) cancer.

20 Accordingly, the present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof as hereinbefore defined for use in therapy.

25 In another aspect, the invention provides the use of a compound of formula (1) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.

30 In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

35 Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or

those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.

The invention further provides a method of effecting immunosuppression (e.g. in the 5 treatment of allograft rejection) which comprises administering to a patient a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof as hereinbefore defined.

The invention still further provides a method of treating, or reducing the risk of, an 10 airways disease (e.g. asthma or COPD) in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (1) or a pharmaceutically-acceptable salt thereof as hereinbefore defined.

15 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. However, in general, for effecting immunosuppression, the daily dosage of the compound of formula (1) will be in the range from 0.1 mg/kg, preferably from 0.3 mg/kg, more preferably from 0.5 mg/kg and still more preferably from 1mg/kg 20 up to and including 30 mg/kg. For the treatment of airways diseases, the daily dosage of the compound of formula (1) will typically be in the range from 0.001 mg/kg to 30 mg/kg.

The compounds of formula (1) and pharmaceutically-acceptable salts thereof may be 25 used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (1) compound/salt/solvate (active ingredient) is in association with a pharmaceutically-acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably less than 80 %w, e.g. from 30 0.10 to 70 %w, and even more preferably less than 50 %w, of active ingredient, all percentages by weight being based on total composition.

Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

- 5 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (1) or a pharmaceutically acceptable salt thereof as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 10 The pharmaceutical composition of the invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
- 15

The ability of compounds which can inhibit PMA/ionomycin-stimulated peripheral blood mononuclear cell proliferation can be assessed, for example using the procedure set out below:

20

The invention will now be illustrated in the following Examples in which, unless otherwise stated:

- 25 (i) evaporation were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;
- 30 (iii) yields are given for illustration only and are not necessarily the maximum attainable;

(iv) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, 5 broad; q, quartet, quin, quintet;

(v) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), mass spectrometry (MS), infra-red (IR) or NMR analysis;

10

Abbreviations


Dimethylformamide	DMF
Tetrahydrofuran	THF

15 The following examples illustrate the invention.

Example 1

2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-

20 one



a) 2-(2-Methyl-1-oxopropyl)-3-thiophenecarboxylic acid

To a solution of thiophene-3-carboxylic acid (26.65g) in THF (300 ml) was added 2M lithium diisopropylamide (229 ml) dropwise at 0-5°C with stirring under nitrogen, and 25 the resulting mixture stirred for 15 min. A solution of N-methoxy-N,2-dimethylpropanamide (30 g) in THF (150 ml) was added dropwise over a period of 1 hr. When the addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 2 hr. It was poured onto water, the layers separated and the

aqueous washed with ether. The aqueous was acidified with conc. hydrochloric acid and extracted with ethyl acetate, the organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as a solid (38.91 g).

5 $\delta^1\text{H}_{\text{DMSO}}$ 1.10 (6H, d), 3.30 (1H, m), 7.37 (1H, d), 7.85 (1H, d)

b) 5-Methyl-7-(1-methylethyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one.

Prepared from a solution of the product of part a) (38.91 g) and methylhydrazine (11.48 ml) in ethanol (200 ml) which was heated at reflux for 2 hr. and concentrated under 10 reduced pressure. The residue was purified by column chromatography over silica, eluting with ethyl acetate / i-hexane (1:4) followed by ethyl acetate / i-hexane (1:1) to give the sub-title compound as a solid (33.09 g).

MS (ESI) 209 [M+H]⁺

15 $\delta^1\text{H}_{\text{CDCl}_3}$ 1.39 (6H, d), 3.13 (1H, septet), 3.85 (3H, s), 7.59 (1H, d), 7.75 (1H, d)

15

c) 2-Bromo-5-methyl-7-(1-methylethyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from a solution of the product of part b) (33.09 g) in acetic acid (100 ml) and water (100 ml) which was treated with bromine (8.16 ml) dropwise over a period of 5 min with stirring under nitrogen. The mixture was heated at 70°C for 6 hr. then cooled, 20 diluted with sodium sulfite solution and extracted with ethyl acetate. The organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with ethyl acetate / i-hexane (1:19) followed by ethyl acetate / i-hexane (1:4) to give the sub-title compound as a solid (13.0 g).

25 MS (ESI) 287 and 289 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.35 (6H, d), 3.01 (1H, septet), 3.82 (3H, s), 7.71 (1H, s)

d) 1-(Diphenylmethyl)-3,5-dimethyl-(1*H*)-pyrazole-4-carboxaldehyde

To a hot solution of 1-(diphenylmethyl)-3,5-dimethyl-(1*H*)-pyrazole (25.0 g) in DMF 30 (22 ml) was added phosphoryl chloride (8.87 ml) dropwise with stirring under nitrogen and the resulting mixture heated at 100°C for 3 hr. It was cooled, diluted with water and dichloromethane and basified with 50% sodium hydroxide with ice/water cooling. It was extracted with dichloromethane, the organic extracts washed with water, dried over

anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with ethyl acetate / i-hexane (1:19) followed by ethyl acetate to give the sub-title compound as a solid (12.61 g).

5 $\delta^1\text{H}_{\text{DMSO}}$ 2.49 (3H, s), 3.58 (3H, s), 6.91 (1H, s), 7.19-7.22 (4H, m), 7.29-7.38 (6H, m), 9.89 (1H, s)

e) 3-Bromo-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]hydroxymethyl]-5-methyl-7-(1-methylethyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one

10 To a solution of the product of part c) (13.0 g) in THF (100 ml) was added 2M lithium diisopropylamide (24.9 ml) dropwise at 0-5°C with stirring under nitrogen, and the resulting mixture stirred for 20 min. A solution of the product of part d) (14.4 g) in THF (50 ml) was added dropwise, the mixture allowed to warm to room temperature and stirred for 3 hr. It was poured into sodium bicarbonate solution and extracted with ethyl acetate, the organic extracts washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with ethyl acetate / i-hexane (1:4) followed by ethyl acetate / i-hexane (1:2) to give the sub-title compound as a solid (17.42 g).
MS (ESI) 577 and 579 [M+H]⁺

15 20 $\delta^1\text{H}_{\text{DMSO}}$ 1.30 (6H, d), 2.00 (3H, s), 2.27 (3H, s), 3.13 (1H, septet), 3.65 (3H, s), 5.88 (1H, d), 6.51 (1H, d), 6.75 (1H, s), 7.10-7.12 (2H, m), 7.17-7.20 (2H, m), 7.25-7.35 (6H, m)

f) 3-Bromo-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-ylmethyl]-5-methyl-7-(1-

25 methylethyl]-thieno[2,3-*d*]pyridazin-4(5*H*)-one

To a solution of the product of part e) (17.42 g) in dichloromethane (36 ml) and trifluoroacetic acid (72 ml) was added triethylsilane (36 ml) and the mixture heated at 40°C with stirring under nitrogen for 48 hr. The solvent was removed under reduced pressure, the residue dissolved in ethyl acetate, washed successively with saturated sodium bicarbonate solution and water, dried over magnesium sulfate, filtered and evaporated under reduced pressure. The solid residue was triturated with i-hexane, collected by filtration and dried, to give the sub-title compound (16.19 g)
MS (ESI) 561 and 563 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.23 (6H, d), 2.04 (3H, s), 2.20 (3H, s), 2.98 (1H, septet), 3.66 (3H, s), 3.97 (2H, s), 6.79 (1H, s), 7.16-7.18 (4H, m), 7.27-7.36 (6H, m)

g) 2-[1-(Diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-ylmethyl]-4,5-dihydro-5-methyl-

5 7-(1-methylethyl)-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

To a solution of the product of part f) (16.19 g) in anhydrous THF (200 ml) was added 2M isopropylmagnesium chloride solution (15.87 ml) dropwise at 0-5°C with stirring under nitrogen, and the resulting mixture stirred at 0°C for 30 min. It was then quenched with a stream of carbon dioxide for 2 hr, allowing the mixture to warm to room 10 temperature. It was concentrated under reduced pressure and diluted with 1M hydrochloric acid. It was extracted with ethyl acetate, the organic extracts washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as a solid (15.18 g)

MS (ESI) 527 [M+H]⁺

15 $\delta^1\text{H}_{\text{DMSO}}$ 1.26 (6H, d), 2.03 (3H, s), 2.17 (3H, s), 3.07 (1H, septet), 3.82 (3H, s), 4.40 (2H, s), 6.82 (1H, s), 7.15-7.20 (4H, m), 7.28-7.38 (6H, m), 16.24 (1H, s, br)

h) 2-[3,5-Dimethyl-1*H*-pyrazol-4-ylmethyl]-4,5-dihydro-5-methyl-7-(1-methylethyl)-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

20 To a solution of the product of part g) (15.18 g) in ethanol (100 ml) and formic acid (50 ml), under nitrogen, was added a catalytic amount of 10% palladium on alumina and the mixture stirred at ambient temperature for 18 h. The catalyst was removed by filtration, fresh catalyst added to the filtrate under nitrogen and the mixture stirred for 24 hr. It was filtered and the solvent removed under reduced pressure to give the sub-title 25 compound as a solid (8.23 g)

MS (ESI) 361 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.24 (6H, d), 2.08 (6H, s), 3.10 (1H, pent), 3.81 (3H, s), 4.36 (2H, s)

i) 2-[3,5-Dimethyl-1*H*-pyrazol-4-ylmethyl]-3-[(4*S*)-4-hydroxy-2-

30 isoxazolidinyl]carbonyl]-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one

To a suspension of the product of part h) (7.13 g), (S)-4-isoxazolidinol hydrochloride (2.73 g), and 1-hydroxybenzotriazole (3.33 g) in acetonitrile (250 ml) was added triethylamine (12.12 ml) followed by diethyl chlorophosphate (3.16 ml) and the mixture

stirred at ambient temperature under nitrogen for 18 hr. It was concentrated under reduced pressure, diluted with saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic extracts were washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was 5 purified by column chromatography over silica, eluting with ethyl acetate / methanol (49:1) followed by ethyl acetate / methanol (19:1) to give the title compound as a solid (2.1 g).


MS (APCI) 432 [M+H]⁺

δ¹H_{DMSO} 1.23-1.26 (6H, m), 2.07-2.11 (6H, m), 2.98-3.04 (1H, m), 3.48-4.16 (9H, m),
10 4.67-4.79 (1H, m), 5.51-5.55 (1H, m), 12.16 (1H, s, br)

Example 2

2-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-3-[(4S)-4-hydroxy-2-
isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)thieno[2,3-d]pyridazin-4(5H)-

15 **one**



a) 2-Bromo-5-methyl-7-(2-methylpropyl)thieno[2,3-d]pyridazin-4(5H)-one

20 Prepared from 5-methyl-7-(2-methylpropyl)thieno[2,3-d]pyridazin-4(5H)-one (WO 9929695) following the procedure of example 1, part c) to give the sub-title compound as a solid.

MS(ESI) 301 and 303 [M+H]⁺

δ¹H_{CDCl3} 0.98 (6H, d), 2.19 (1H, septet), 2.59 (2H, d), 3.82 (3H, s), 7.69 (1H, s)

b) 3-Bromo-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]hydroxymethyl]-5-methyl-7-(2-methylpropyl)thieno[2,3-*d*]pyradizin-4(5*H*)-one

Prepared from the product of part a) following the procedure of example 1 part e) to give the sub-title compound as a solid.

5 $\delta^1\text{H}_{\text{DMSO}}$ 0.94-0.96 (6H, m), 1.99 (3H, s), 2.11 (1H, septet), 2.26 (3H, s), 2.61-2.68 (2H, m), 3.66 (3H, s), 5.88 (1H, d), 6.53 (1H, d), 6.91 (1H, s), 7.10-7.20 (4H, m), 7.25-7.38 (6H, m)

c) 3-Bromo-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-5-methyl-7-(2-methylpropyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one

10 Prepared from the product of part b) following the procedure of example 1 part f) to give the sub-title compound as a solid.

MS(ESI) 575 and 577 $[\text{M}+\text{H}]^+$

15 $\delta^1\text{H}_{\text{DMSO}}$ 0.88 (6H, d), 1.99 (3H, s), 1.99-2.04 (1H, m), 2.15 (3H, s), 3.66 (3H, s), 3.97 (2H, s), 6.80 (1H, s), 7.15-7.37 (6H, m)

d) 2-[[1-(Diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-4,5-dihydro-5-methyl-7-(2-methylpropyl)-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

20 Prepared from the product of part c) following the procedure of example 1 part g) to give the sub-title compound as a solid.

MS(ESI) 541 $[\text{M}+\text{H}]^+$

e) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-4,5-dihydro-5-methyl-7-(2-methylpropyl)-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

25 Prepared from the product of part d) following the procedure of example 1 part h) to give the sub-title compound as a solid.

MS(ESI) 375 $[\text{M}+\text{H}]^+$

$\delta^1\text{H}_{\text{DMSO}}$ 0.89 (6H, d), 2.07-2.13 (7H, m), 2.62 (2H, d), 3.81 (3H, s), 4.34 (2H, s)


30 f) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one
Prepared from the product of part e) following the procedure of example 1 part i) to give the title compound as a solid.

MS(APCI) 446 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.89-0.91 (6H, m), 2.04-2.12 (7H, m), 2.55-2.58 (2H, m), 3.48-4.16 (9H, m), 4.63-4.80 (1H, m), 5.52 (1H, s, br)

5 **Example 3**

2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one



10

a) N-methoxy-N-methylpropanamide

To a solution of propanoyl chloride (15ml) in DCM (250ml) under nitrogen was added *N,N*-dimethylhydroxylamine (17g) and triethylamine (72ml) at 0°C with stirring. The resulting mixture was allowed to warm to room temperature over 5h then filtered, the 15 filtrate evaporated under reduced pressure and then triturated with diethyl ether. The resulting filtrate was evaporated under reduced pressure to give the sub-title compound as an oil (17.7g)

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.14 (3H, t), 2.43 (2H, q), 3.08 (3H, s), 3.67 (3H, s)

b) 2-(1-Oxopropyl)-3-thiophenecarboxylic acid

20 Prepared from thiophene-3-carboxylic acid and the product of part a) following the procedure of example 1, part a) to give the sub-title compound as a solid.

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.91 (3H, t), 3.18 (2H, q), 7.64 (1H, d), 7.98 (1H, d)

c) 5-Methyl-7-ethyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

25 Prepared from the product of part b) following the procedure of example 1, part b) to give the sub-title compound as a solid.

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.38 (3H, t), 2.86 (2H, q), 3.85 (3H, s), 7.60 (1H, d), 7.75 (1H, d)

d) 2-Bromo-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from a solution of the product of part c) (4.8g) in DCM (50ml) which was treated with methanesulfonic acid (0.8ml) and 1,3-dibromo-5,5-dimethylhydantoin (3.5g). The mixture was stirred under nitrogen, in the dark, for 20h. Additional methanesulfonic acid (0.8ml) and 1,3-dibromo-5,5-dimethylhydantoin (3.5g) were added and the mixture stirred for a further 20h. The mixture was diluted with DCM and successively washed with sodium thiosulfate solution (x2) then brine, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with iso-hexane/ethyl acetate (9:1) followed by iso-hexane/ethyl acetate (8:2) to give the sub-title compound as a solid (3g).

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.35 (3H, t), 2.77 (2H, q), 3.82 (3H, s), 7.70 (1H, s)

15 e) 3-Bromo-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]hydroxymethyl]-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part d) following the procedure of example 1, part e) to give the sub-title compound as a solid.

MS (ESI) 563 and 565 [M+H]⁺

20 $\delta^1\text{H}_{\text{CDCl}_3}$ 1.35 (3H, t), 2.15 (3H, s), 2.23 (3H, s), 2.81 (2H, q), 3.80 (3H, s), 6.04 (1H, s), 6.56 (1H, s), 7.08-7.17 (4H, m), 7.26-7.35 (6H, m)

f) 3-Bromo-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

25 Prepared from the product of part e) following the procedure of example 1, part f) to give the sub-title compound as a solid.

MS (ESI) 547 and 549 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.28 (3H, t), 2.10 (3H, s), 2.18 (3H, s), 2.74 (2H, q), 3.80 (3H, s), 3.93 (2H, s), 6.91 (1H, s), 7.15 (4H, m), 7.33 (6H, m)

g) 2-[[1-(Diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

Prepared from the product part f) following the procedure of example 1, part g) to give the sub-title compound as a solid.

5 MS (ESI) 513 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.34 (3H, t), 2.07 (3H, s), 2.15 (3H, s), 2.79 (2H, q), 3.93 (3H, s), 4.55 (2H, s), 6.64 (1H, s), 7.17 (4H, m), 7.32 (6H, m)

h) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxo-

10 thieno[2,3-*d*]pyridazine-3-carboxylic acid

Prepared from the product of part g) following the procedure of example 1, part h) to give the sub-title compound as a solid.

MS (ESI) 347 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.22 (3H, t), 2.08 (6H, s), 2.79 (2H, q), 3.81 (3H, s), 4.32 (2H, s)

15

i) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one


Prepared from the product of part h) following the procedure of example 1, part i) to give the sub-title compound as a solid.

20 MS (ESI) 418 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.23 (3H, m), 2.05 (3H, m), 2.13 (3H, m), 2.74 (2H, m), 3.33 (3H, s), 3.51-4.16 (6H, m), 4.61-4.82 (1H, m), 5.55 (1H, m).

Example 4

25 7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one



a) N-methoxy-N-methyl-cyclopropanecarboxamide

Prepared from cyclopropanecarbonyl chloride following the procedure of example 3, part a) to give the sub-title compound as an oil.

5 $\delta^1\text{H}_{\text{CDCl}_3}$ 0.81 (2H, m), 0.99 (2H, m), 2.14 (1H, m), 3.21 (3H, s), 3.67 (3H, s)

b) 2-(Cyclopropylcarbonyl)-3-thiophenecarboxylic acid

Prepared from thiophene-3-carboxylic acid and the product of part a) following the procedure of example 1, part a) to give the sub-title compound as a solid.

10 $\delta^1\text{H}_{\text{CDCl}_3}$ 1.31 (2H, m), 1.48 (2H, m), 2.59 (1H, m), 7.70 (1H, d), 7.98 (1H, d)

c) 7-Cyclopropyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part b) following the procedure of example 1, part b) to give the sub-title compound as a solid.

15 MS (ESI) 207 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.02 (2H, m), 1.08 (2H, m), 2.02 (1H, m), 3.78 (3H, s), 7.59 (1H, d), 7.75 (1H, d)

d) 2-Bromo-7-cyclopropyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

20 Prepared from a rapidly stirred solution of the product of part c) (9.0g) in saturated sodium bicarbonate solution (150ml), treated with bromine 6.7ml. After 25min. sodium metabisulfite solution was added dropwise and with stirring and sonicating a solid was formed. The resulting solid was filtered, washed with water, dried in a vacuum oven and purified by column chromatography over silica, eluting with iso-hexane/ethyl acetate (9:1) to give the sub-title compound as a solid (8.0g).

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.04 (4H, m), 1.84 (1H, m), 3.77 (3H, s), 7.69 (1H, s)

e) 3-Bromo-7-cyclopropyl-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]hydroxymethyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

30 Prepared from the product of part d) following the procedure of example 1, part e) to give the sub-title compound as a solid.

MS (ESI) 575 and 577 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.05 (4H, m), 1.92 (1H, m), 2.17 (3H, s), 2.24 (3H, s), 3.75 (3H, s), 6.06 (1H, s), 6.57 (1H, s), 7.15 (4H, m), 7.32 (6H, m)

f) 3-Bromo-7-cyclopropyl-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

5 Prepared from the product of part e) following the procedure of example 1, part f) to give the sub-title compound as a solid.

MS (ESI) 559 and 561 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 0.98 (4H, m), 1.83 (1H, m), 2.13 (3H, s), 2.19 (3H, s), 3.75 (3H, s), 3.94 (3H,

10 s), 6.61 (1H, s), 7.16 (4H, m), 7.31 (6H, m)

g) 7-Cyclopropyl-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-4,5-dihydro-5-methyl-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

15 Prepared from the product of part f) following the procedure of example 1, part g) to give the sub-title compound as a solid.

MS (ESI) 525 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.06 (4H, m), 1.87 (1H, m), 2.05 (3H, s), 2.19 (3H, s), 3.84 (3H, s), 4.56 (2H, s), 6.63 (1H, s), 7.18 (4H, m), 7.35 (6H, m)

20 h) 7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-4,5-dihydro-5-methyl-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

Prepared from the product of part g) following the procedure of example 1, part h) to give the sub-title compound as a solid.

MS (ESI) 359 [M+H]⁺

25 $\delta^1\text{H}_{\text{DMSO}}$ 0.95 (4H, m), 2.18 (6H, s), 2.20 (1H, m), 3.77 (3H, s), 4.39 (2H, s)

i) 7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one


30 Prepared from a solution of part h) following the procedure of example 1, part i) to give the title compound as a solid.

MS (ESI) 430 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.92 (4H, m), 2.03 (3H, m), 2.14 (3H, m), 3.32 (3H, s), 3.50-4.14 (6H, m), 4.56-4.79 (1H, m), 5.54 (1H, m)

Example 5

5 **7-Cyclopropyl-2-[{(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-5-ethyl-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one**



a) 7-Cyclopropyl-5-ethyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from a suspension of the product of example 4, part b) (12.0g) in ethanol (150ml) which was treated with triethylamine (19ml) and ethylhydrazine oxalate (9.9g). The mixture was refluxed for 6hr, then allowed to cool and evaporated under reduced pressure. The resulting oil was partitioned between 1N sodium hydroxide solution and dichloromethane. The organic layer was separated, washed with 1N sodium hydroxide solution, brine and then water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as an oil (10.8g).

MS (ESI) 221 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.02 (2H, m), 1.11 (2H, m), 1.38 (3H, t), 2.02 (1H, m), 4.24 (2H, q), 7.58 (1H, d), 7.75 (1H, d)

20 **b) 2-Bromo-7-cyclopropyl-5-ethyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one**

Prepared from the product of part a) following the procedure of example 4, part d) to give the sub-title compound as a solid.

MS (ESI) 299 and 301 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.04 (4H, m), 1.37 (3H, t), 1.84 (1H, m), 4.20 (2H, q), 7.70 (1H, s)

25

c) 3-Bromo-7-cyclopropyl-2-[(1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl)hydroxymethyl]-5-ethyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part b) following the procedure of example 1, part e) to give the sub-title compound as a solid.

MS (ESI) 895 and 591 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.01 (2H, m), 1.05 (2H, m), 1.37 (3H, t), 1.92 (1H, m), 2.18 (3H, s), 2.24 (3H,

5 s), 4.19 (2H, m), 6.06 (1H, s), 6.57 (1H, s), 7.09 (2H, m), 7.12 (2H, m), 7.31 (6H, m)

d) 3-Bromo-7-cyclopropyl-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-5-ethyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part c) following the procedure of example 1, part f) to

10 give the sub-title compound as a solid.

MS (ESI) 573 and 575 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 0.97-1.05 (4H, m), 1.35 (3H, t), 1.82 (1H, m), 2.12 (3H, s), 2.17 (3H, s), 3.94 (2H, s), 4.19 (2H, q), 6.61 (1H, s), 7.16 (4H, m), 7.35 (6H, m)

15 **e) 7-Cyclopropyl-2-[[1-(diphenylmethyl)-3,5-dimethyl-1*H*-pyrazol-4-yl]methyl]-5-ethyl-4,5-dihydro-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid**

Prepared from the product of part d) following the procedure of example 1, part g) to give the sub-title compound as a solid.

MS (ESI) 539 [M+H]⁺

20 $\delta^1\text{H}_{\text{CDCl}_3}$ 1.04 (4H, m), 1.39 (3H, t), 1.88 (1H, m), 2.06 (3H, s), 2.15 (3H, s), 4.28 (2H, q), 4.56 (2H, s), 6.65 (1H, s), 7.17 (4H, m), 7.34 (6H, m)

f) 7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-5-ethyl-4,5-dihydro-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

25 Prepared from the product of part e) following the procedure of example 1, part h) to give the sub-title compound as a solid.

MS (ESI) 373 [M+H]⁺

g) 7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-5-ethyl-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from a solution of the product of part f) (260mg) in dichloromethane (4ml) which was treated with (*S*)-4-isoxazolidinol hydrochloride (105mg), PyBrOP (285mg) and triethylamine (0.23ml) and stirred at room temperature for 3 days. The reaction


mixture was directly purified by column chromatography over silica, eluting with dichloromethane/methanol 98:2 followed by dichloromethane/methanol 96:4 then preparative reverse phase HPLC using acetonitrile/aq. ammonia to give the title compound as a solid (80mg).

5 MS (ESI) 444M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.93 (4H, m), 1.37-1.43 (3H, m), 1.97-2.16 (7H, m), 3.58-3.94 (9H, m), 5.39-5.60 (1H, m), 12.17 (1H, bs)

Example 6

10 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one



a) 2-[(2*S*)-2-Methyloxiranyl]methoxy]-1*H*-isoindole-1,3(2*H*)-dione

15 A mixture of N-hydroxypythalimide (5.3g), [(2*S*)-2-methyloxiran-2-yl]methyl 3-nitrobenzenesulfonate (5.9g) and triethylamine (10.6ml) in dichloromethane (15ml) was stirred under nitrogen at ambient temperature for 24hours. The reaction mixture was poured onto a silica column and eluted with dichloromethane to give the sub-title compound as a colourless solid (3.1g).

20 MS (APCI) 234 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.63 (3H, s), 2.69 (1H, d), 2.76 (1H, d), 4.17 (1H, d), 4.21 (1H, d), 7.73-7.78 (2H, m), 7.82-7.87 (2H, m)

b) 2-[(2*R*)-3-Chloro-2-hydroxy-2-methylpropyl]oxy]- 1*H*-isoindole-1,3(2*H*)-dione

25 The product of part a) (3.0g) was treated with concentrated hydrochloric acid (12ml) and stirred at ambient temperature for 2hours. The mixture was partitioned between water and dichloromethane, the organics were dried and purified by chromatography (EtOAc) to give the sub-title compound as a colourless solid (3.3g).

$\delta^1\text{H}_{\text{DMSO}}$ 1.29(3H, s), 3.67 (1H, d), 3.76 (1H, d), 4.09 (1H, d), 4.15 (1H, d), 7.86 (4H, s), 5.24 (1H, s)

c) 2-[(4S)-4-Hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]- benzoic acid methyl ester

5 Prepared from a solution of the product of part b) (3.3. g) in methanol (25 ml) which was treated with triethylamine (3.4 ml) and heated under nitrogen at reflux for 1 hour. The mixture was concentrated to dryness and purified by chromatography over silica eluting with a gradient from dichloromethane to 5% methanol in dichloromethane. The chiral purity of the product was enhanced by recrystallising twice from acetonitrile to give the 10 sub-title compound as a colourless solid (1.92 g).

HPLC: (9010THIP.M) 50mm chiracel AD column, ee >99%

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.52 (3H, s), 3.59 (1H, d), 3.81 (1H, d), 3.88 (1H, d), 4.04 (1H, s), 4.34 (1H, d), 3.92 (3H, s), 7.45 (1H, d), 7.49 (1H, t), 7.62 (1H, t), 8.00 (1H, d).

15 d) (4S)-4-Methyl-4-isoxazolidinol hydrochloride

Prepared from a solution of the product of part c) (4.9g) in 2N hydrochloric acid (30 ml) which was heated under nitrogen at reflux for 4 hours. After cooling the precipitate was removed by filtration and the liquors concentrated to dryness under vacuo. The residue was triturated with acetonitrile to give the sub-title compound as a white solid (1.79 g).

20 $\delta^1\text{H}_{\text{DMSO}}$ 1.42 (3H, s), 3.29 (1H, d), 3.41 (1H, dd), 3.87 (1H, d), 4.05 (1H, dd).

e) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4S)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(5*H*)-one


To a solution of the product of part d) (85 mg), the product of example 1 part h) (201 25 mg) and PyBroP (285 mg) in DCM (5 ml) was added triethylamine (0.23 ml) and the mixture stirred at room temperature under nitrogen for 18 hr. It was concentrated in vacuo and the residue was purified by column chromatography over silica, eluting with ethyl acetate / methanol (50:1) to give the title compound as a solid (129 mg).

MS (APCI) 446 [M+H]⁺

30 $\delta^1\text{H}_{\text{DMSO}}$ 1.18-1.44 (9H, m), 2.08 (6H, d), 2.98-3.10 (2H, m), 3.57-4.00 (8H, m), 5.40 (0.66H, s), 5.76 (0.33H, s), 12.15 (1H, s, br)

Example 7

2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one



5

a) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one


Prepared from the product of example 2 part e) following the procedure of example 6 part e) to give the title compound as a solid.

10 MS(APCI) 460 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.90 (6H, d), 1.27-1.44 (3H, m), 2.04-2.12 (7H, m), 2.55-2.59 (2H, m), 3.57-3.93 (9H, m), 5.40 (0.66H, s), 5.59 (0.33H, s), 12.16 (1H, s)

15 Example 8

2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one



20 a) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

Prepared from the product of example 3, part g) (1.0g) in trifluoroacetic acid (10ml) under reflux for 20hrs. The resulting mixture was evaporated under reduced pressure, azeotroping with dichloromethane (x3). The residue was triturated with water and then with ether, and the solid was collected and dried to give the sub-title compound as a 5 solid (580mg).

MS (ESI) 347 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.22 (3H, t), 2.01 (6H, s), 2.80 (2H, q), 3.83 (3H, s), 4.39 (2H, s)

b) 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-4-methyl-2-10 isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one


Prepared from the product of part a) following the procedure of example 6, part e) to give the title compound as a solid.

MS (ESI) 432 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.21 (3H, m), 1.25-1.44 (3H, m), 2.07 (6H, bs), 2.75 (2H, m), 3.63-3.94 (9H, 15 m), 5.39-5.60 (1H, m), 12.16 (1H, bs)

Example 9

7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one



20

a) 7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one


Prepared from the product of example 4, part h) following the procedure of example 6, 25 part e) to give the title compound as a solid.

MS (ESI) 444 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.93 (4H, m), 1.37-1.43 (3H, m), 1.97-2.16 (7H, m), 3.58-3.94 (9H, m), 5.39-5.60 (1H, m), 12.17 (1H, m)

Example 10

5 3-[(4S)-4-hydroxyisoxazolidinyl]carbonyl-5-methyl-7-(2-methylpropyl)-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one



10 a) 3-Bromo-2-[hydroxy[1-(phenylsulphonyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]methyl]-5-methyl-7-(2-methylpropyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one

To a solution of the product of example 2 part a) (0.22 g) in anhydrous THF (5 ml) was added 2.0M LDA (0.44 ml) at -78°C under nitrogen with stirring. After 20 mins a solution of 1-(phenylsulphonyl)1*H*-pyrrolo[2,3-*b*]pyridine-3-carboxaldehyde (0.23 g) in anhydrous THF (5 ml) was added and the mixture stirred at room temperature for 18 hr.

15 It was poured into water and extracted with ethyl acetate. The organic extracts were washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with i-hexane / ethyl acetate (1:1) to give the sub-title compound (0.2 g).
MS (ESI) 587 and 589 [M+H]⁺

20 b) 3-Bromo-5-methyl-7-(2-methylpropyl)-2-[(1-(phenylsulphonyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)methyl]-thieno[2,3-*d*]pyridazin-4(5*H*)-one

To a solution of the product of part a) (0.2 g) in DCM (0.5 ml) was added triethylsilane (0.5 ml) and trifluoroacetic acid (1.0 ml) and the mixture stirred at 40°C for 24 hr. It was concentrated in vacuo, diluted with sodium hydrogen carbonate solution and extracted with DCM. The organic extracts were washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The

residue was purified by column chromatography over silica, eluting with i-hexane / ethyl acetate (3:1) to give the sub-title compound (0.17 g).

MS (ESI) 571 and 573 [M+H]⁺

δ¹H_{CDCl} 0.94 (6H, d), 2.12 (1H, septet), 2.52 (2H, d), 3.82 (3H, s), 4.30 (2H, s), 7.14-5 7.19 (1H, m), 7.47-7.61 (3H, m), 7.66 (1H, s), 7.76 (1H, dd), 8.20 (2H, d), 8.45 (1H, dd)

c) 4,5-Dihydro-5-methyl-7-(2-methylpropyl)-4-oxo-2-[[1-(phenylsulphonyl)-1H-pyrrolo[2,3-*b*]pyridin-3-yl]methyl]-thieno[2,3-*d*]pyridazine-3-carboxylic acid

To a solution of the product of part b) (0.17 g) in anhydrous THF (8 ml) was added 2.0M 10 isopropylmagnesium chloride (0.164 ml) at 0°C and the mixture stirred for 5 mins. It was quenched with a stream of carbon dioxide for 45 mins. It was poured into water, acidified with dilute hydrochloric acid, and extracted with DCM. The organic extracts were washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as a solid (0.16 g).

15 MS (ESI) 537 [M+H]⁺

d) 4,5-dihydro-5-methyl-7-(2-methylpropyl)-4-oxo-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)thieno[2,3-*d*]pyridazine-3-carboxylic acid

A solution of the product of part c) (0.16 g) in methanol (5 ml) was treated with 20 potassium hydroxide (50 mg) and heated under reflux for 1.5 hr. It was concentrated in vacuo, acidified with dilute hydrochloric acid and extracted with DCM. The organic extracts were washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as a solid (0.10 g).

MS (ESI) 397 [M+H]⁺

25

e) 3-[[4S)-4-Hydroxyisoxazolidin-2-yl]carbonyl]-5-methyl-7-(2-methylpropyl)-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)-thieno[2,3-*d*]pyridazin-4(5*H*)-one

To a stirred suspension of the product of part d) (50 mg) in DCM (2 ml) under nitrogen was added 1-hydroxybenzotriazole hydrate (39 mg) and after 15 mins EDCI (48 mg) 30 added and the mixture stirred for 1 hour. (S)-4-Isoxazolidinol hydrochloride (32 mg) and triethylamine (53μl) were added and the mixture stirred overnight. It was diluted with water and extracted with DCM. The organic extracts were washed with water, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced

pressure. The residue was purified by column chromatography over silica, eluting with ethyl acetate / methanol (50:1) to give the title compound as a solid (19 mg).


MS(APCI) 468 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.85-0.87 (6H, m), 1.99-2.05 (1H, septet), 2.50 (2H, m), 3.55-3.62 (1H, m),

5 3.66 (3H, d), 3.73-3.78 (1H, m), 3.95-3.98 (1H, m), 4.14-4.19 (1H, m), 4.30-4.39 (2H, m), 4.67 (0.4H, m), 4.81 (0.6H, m), 5.55 (1H, s, br), 7.00-7.03 (1H, m), 7.45-7.49 (1H, m), 7.89-7.94 (1H, m), 8.20-8.21 (1H, m), 11.59 (1H, s)

Example 11

10 3-[(4S)-4-Hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-2-[1,3,5-trimethylpyrazol-4-yl)methyl]-thieno[2,3-d]pyridazin-4(5H)-one



15 a) 3-Bromo-2-[hydroxy(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-5-methyl-7-(2-methylpropyl)-thieno[2,3-d]pyridazin-4(5H)-one

Prepared from the product of example 2 part a) and 1,3,5-pyrazole-4-carboxaldehyde by the method of example 10 part a) to give the sub-title compound.

MS (ESI) 439 and 441 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.93-0.96 (6H, m), 2.01 (3H, s), 2.13 (1H, septet), 2.17 (3H, s), 2.59-2.69 (2H, m), 3.61 (3H, s), 3.66 (3H, s), 5.84 (1H, d), 6.43 (1H, d)

b) 3-Bromo-5-methyl-7-(2-methylpropyl)-2-[1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]-thieno[2,3-d]pyridazin-4(5H)-one

20 Prepared from the product of part a) by the method of example 10 part b) to give the sub-title compound.

MS (ESI) 423 and 425 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.88 (6H, d), 2.01 (3H, s), 2.05 (1H, septet), 2.17 (3H, s), 2.50-2.54 (2H, m), 3.66 (3H, s), 3.67 (3H, s), 3.93 (3H, s)

c) 4,5-Dihydro-5-methyl-7-(2-methylpropyl)-4-oxo-2-[(1,3,5-trimethyl-1*H*-pyrazol-4-yl)methyl]-thieno[2,3-*d*]pyridazine-3-carboxylic acid

Prepared from the product of part b) by the method of example 10 part c) to give the
5 sub-title compound as a solid.

MS (ESI) 389 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 0.88 (6H, d), 2.00 (3H, s), 2.06 (1H, septet), 2.14 (3H, s), 2.56 (2H, d), 3.68 (3H, s), 3.82 (3H, s), 4.36 (2H, s), 16.20 (1H, s, br)

10 d) 3-[(4*S*)-4-Hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-2-[(1,3,5-trimethylpyrazol-4-yl)methyl]-thieno[2,3-*d*]pyridazin-4(5*H*)-one


Prepared from the product of part c) by the method of example 10 part e) to give the title
compound as a solid.

MS (APCI) 460 [M+H]⁺

15 $\delta^1\text{H}_{\text{DMSO}}$ 0.90 (6H, d), 2.00-2.14 (7H, m), 2.56 (2H, d), 3.48-4.16 (12H, m), 4.60-4.82 (1H, m), 5.50-5.60 (1H, m)

Example 12

20 2-[(3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one



a) 2-Bromo-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of example 3, part b) following the procedure of example 4,
25 part d) to give the sub-title compound as a solid.

MS (ESI) 273 and 275 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.35 (3H, t), 2.77 (2H, q), 3.82 (3H, s), 7.70 (1H, s)

b) 3-(1,3-Dithian-2-ylidene)-2,4-pentanedione

To a solution of 2,4-pentanedione (10.5ml) in dimethylformamide (200ml) was added 5 potassium carbonate (42.5g) then carbon disulfide (9.3ml). To the resulting mixture was added 1,3-dibromopropane, dropwise over 40min. The mixture was stirred at ambient temperature under a nitrogen atmosphere for 20hrs. then ice/water (200ml) was added and the suspension was stirred for 1hr. The solid was collected by filtration, washed 10 with water and then recrystallised from ethanol to give the sub-title compound as a solid (23.3g).

MS (ESI) 217 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 2.28 (2H, pentet), 2.34 (6H s), 2.95 (4H, t)

c) 3-(1,3-Dithian-2-yl)-2,4-pentanedione

15 To an ice-cooled suspension of the product of part b) (23.3g) in dry methanol was added magnesium turnings (9.0g) portionwise and the resulting mixture was stirred at ambient temperature under a nitrogen atmosphere for 18hrs. The mixture was evaporated under reduced pressure, then water (500ml) was added and the mixture was acidified to pH1 with concentrated hydrochloric acid with stirring. The aqueous mixture was extracted 20 with dichloromethane (x2) and the combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with iso-hexane/ethyl acetate (9:1) and then recrystallised from isopropyl alcohol to give the sub-title compound as a solid (4.0g).

25 $\delta^1\text{H}_{\text{CDCl}_3}$ 2.03 (2H, m), 2.25 (6H s), 2.78 (2H, m), 2.94 (2H, m), 4.32 (1H, d), 4.51 (1H, d)

d) 2-[4-(1,3-Dithian-2-yl)-3,5-dimethyl-1*H*-pyrazol-1-yl]-pyridine

Prepared from a solution of the product of part c) (2.8g) and 2-pyridylhydrazine (1.55g) 30 in ethanol (20ml) stirred at ambient temperature for 19hrs and then heated to reflux for 1hr. After evaporation the residue was purified by column chromatography over silica, eluting with iso-hexane/ethyl acetate (8:2) to give the sub-title compound as a solid (1.4g).

MS (ESI) 292 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.92 (1H, s), 2.16 (1H, m), 2.44 (3H, s), 2.74 (3H, s), 2.88 (2H, dt), 3.06 (2H, m), 5.26 (1H, s), 7.17 (1H, m), 7.77 (2H, m), 8.42 (1H, m)

5 e) 3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazole-4-carboxaldehyde

Prepared from a solution of the product of part d) in acetonitrile (80ml) and water (10ml) with addition of N-bromosuccinimide (1.22g) at 0°C. The resulting mixture was stirred for 1.5 hrs. then additional N-bromosuccinimide (0.5g) was added and the mixture stirred for further 1.5hrs. Further N-bromosuccinimide (0.2g) was added and the mixture 10 was stirred for a further 45min. before quenching with sodium sulfite solution. The mixture was extracted with ethyl acetate and the organic solution was washed with water then brine, dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as a solid.

MS (ESI) 202 [M+H]⁺

15 $\delta^1\text{H}_{\text{DMSO}}$ 2.43 (3H, s), 2.83 (3H, s), 7.46 (1H, m), 7.83 (1H, d), 8.04 (1H, td), 8.55 (1H, m), 10.10 (1H, s)

f) 3-Bromo-2-[[3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]hydroxymethyl]-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

20 To a solution of the product of part a) (930mg) in THF (10 ml) was added freshly prepared lithium diisopropylamide (1.6ml n-butyl lithium in hexanes and 0.62ml diisopropylamine in THF 10ml) dropwise at -78°C with stirring under nitrogen, and the resulting mixture was stirred for 20 min. A suspension of the product of part e) (705mg) in THF (10 ml) was added dropwise and the mixture was allowed to warm to room 25 temperature and stirred for 3 hr. It was poured into sodium bicarbonate solution and extracted with ethyl acetate (x3), the organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was triturated with ether to give the sub-title compound as a solid (800mg).

MS (ESI) 474 and 476 [M+H]⁺

30 $\delta^1\text{H}_{\text{DMSO}}$ 1.28 (3H, t), 2.12 (3H, s), 2.63 (3H, s), 2.82 (2H, quartet), 3.66 (3H, s), 5.98 (1H, m), 6.67 (1H, m), 7.33 (1H, m), 7.76 (1H, m), 7.95 (1H, m), 8.46 (1H, m)

g) 3-Bromo-2-[[3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(*H*)-one

Prepared from the product of part f) following the procedure of example 1, part f) to give the sub-title compound as a solid.

5 MS (ESI) 458 and 460 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.19 (3H, t), 2.17 (3H, s), 2.59 (3H, s), 2.73 (2H, quartet), 3.67 (3H, s), 4.07 (2H, s), 7.35 (1H, m), 7.83 (1H, m), 7.96 (1H, m), 8.47 (1H, m)

h) 2-[[3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-4,5-dihydro-5-

10 methyl-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

To a solution of the product of part g) (485 mg) in anhydrous THF (20 ml) was added 2M isopropyl magnesium chloride solution (0.58 ml) dropwise at 0-5°C with stirring under nitrogen, and the resulting mixture was stirred at 0°C for 30 min. It was quenched with a stream of carbon dioxide for 2.5 hr allowing the mixture to warm to room temperature. 2M hydrochloric acid was added and readjusted to pH3 with 1M sodium hydroxide solution. The aqueous mixture was extracted with ethyl acetate, the organic extracts dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was triturated with ether to give the sub-title compound as a solid (175 mg).

15 MS (ESI) 424 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.18 (3H, t), 2.15 (3H, s), 2.56 (3H, s), 2.82 (2H, quartet), 3.83 (3H, s), 4.51 (2H, s), 7.35 (1H, m), 7.85 (1H, m), 7.94 (1H, m), 8.48 (1H, m)

i) 2-[[3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-3-[(4*S*)-4-

25 hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*H*)-one


Prepared from the product of part h) following the procedure of example 5, part g) to give the title compound as a solid.

MS (ESI) 495 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.22 (3H, t), 2.15 (3H, s), 2.57 (3H, s), 2.66 (2H, m), 3.30 (3H, m), 3.49-4.18 (6H, m), 4.56-4.81 (1H, m), 5.52 (1H, m), 7.32 (1H, dt), 7.81 (1H, d), 7.96 (1H, dt), 8.45 (1H, d)

Example 13

2-[[3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one



5

a) 2-[[3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

10 Prepared from the product of example 12 part h) following the procedure of example 6, part e) to give the title compound as a solid.


MS (ESI) 509 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.22 (3H, t), 1.33-1.44 (3H, m), 2.17 (3H, m), 2.57 (3H, s), 2.76 (2H, m), 3.56-4.10 (9H, m), 5.27-5.58 (1H, m), 7.35 (1H, m), 7.81 (1H, m), 7.94 (1H, m), 8.46 (1H, m)

15

Example 14

7-Ethyl-3-[(4*S*)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-5-methyl-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one



20

a) 2-Bromo-7-ethyl-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of example 3, part c) following the procedure of example 4, part d) to give the sub-title compound as a solid.

MS (ESI) 273/275 [M+H]⁺

5 $\delta^1\text{H}_{\text{CDCl}_3}$ 1.35 (3H, t), 2.77 (2H, q), 3.82 (3H, s), 7.70 (1H, s)

b) 3-Bromo-7-ethyl-2-{\hydroxy[1-(phenylsulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]methyl}-5-methylthieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part a) following the procedure of example 10, part a) to 10 give the sub-title compound as a solid.

MS (ESI) 559/561 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.16 (3H, t), 2.79 (2H, q), 3.65 (3H, s), 6.62 (1H, m), 7.06 (1H, m), 7.33 (1H, m), 7.62 (2H, m), 7.74 (1H, m), 7.84 (1H, s), 8.02 (1H, dd), 8.10 (2H, m), 8.38 (1H, m)

c) 3-Bromo-7-ethyl-5-methyl-2-{\[1-(phenylsulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]methyl}thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part b) following the procedure of example 10, part b) to give the sub-title compound as a solid.

MS (ESI) 543/545 [M+H]⁺

20 $\delta^1\text{H}_{\text{DMSO}}$ 1.18 (3H, t), 2.65 (2H, q), 3.64 (3H, s), 4.42 (2H, s), 7.35 (1H, m), 7.61 (2H, m), 7.71 (1H, m), 7.95 (1H, s), 7.98 (1H, dd), 8.07 (2H, m), 8.39 (1H, m)

d) 7-Ethyl-5-methyl-4-oxo-2-{\[1-(phenylsulfonyl)-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl]methyl}-4,5-dihydrothieno[2,3-*d*]pyridazine-3-carboxylic acid

25 Prepared from the product of part c) following the procedure of example 10, part c) to give the sub-title compound as a solid.

MS (ESI) 509 [M+H]⁺

$\delta^1\text{H}_{\text{DMSO}}$ 1.25 (3H, m), 2.73 (2H, m), 3.71 (3H, s), 4.82 (2H, s), 7.26 (1H, m), 7.63 (3H, m), 7.74 (1H, m), 7.98 (1H, s), 8.04 (2H, m), 8.37 (1H, m)

e) 7-Ethyl-5-methyl-4-oxo-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)-4,5-dihydrothieno[2,3-*d*]pyridazine-3-carboxylic acid

A solution of the product of part d) (0.23 g) in methanol (10 ml) was treated with 5 potassium hydroxide (76 mg) and heated under reflux for 3 hr. It was concentrated in vacuo, diluted with water and extracted with ethyl acetate (x2). The aqueous layer was acidified to pH5 using glacial acetic acid and extracted with ethyl acetate (x3). The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give the sub-title compound as a solid (0.064 g).

10 MS (ESI) 369 [M+H]⁺

f) 7-Ethyl-3-[(4*S*)-4-hydroxy-4-methylisoxazolidin-2-yl]carbonyl]-5-methyl-2-(1*H*-pyrrolo[2,3-*b*]pyridin-3-ylmethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one

To a solution of the product of part e) (0.08 g), and 1-hydroxybenzotriazole (0.037 g) in 15 dimethylformamide (2 ml) was added triethylamine (0.135 ml) followed by diethyl chlorophosphate (0.035 ml) and the mixture was stirred at ambient temperature under nitrogen for 1.5 hr. (4*S*)-4-Methyl-4-isoxazolidinol hydrochloride (0.033 g) was added and the mixture was stirred at ambient temperature under nitrogen for 20 hr. It was diluted with saturated sodium bicarbonate solution and extracted with DCM (x3). The 20 organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The residue was purified by column chromatography over silica, eluting with DCM / methanol (98:2) followed by DCM / methanol (96:4) to give the title compound as a solid (0.05g).


MS (ESI) 454 [M+H]⁺

25 $\delta^1\text{H}_{\text{DMSO}}$ 1.17 (3H, m), 1.32-1.46 (3H, m), 2.70 (2H, q), 3.65 (3H, m), 3.72-3.83 (4H, m), 4.36 (2H, m), 5.23-5.62 (1H, m), 7.02 (1H, m), 7.48 (1H, m), 7.92 (1H, m), 8.20 (1H, dd), 11.58 (1H, bs)

Example 15

2-[(3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one

5



a) 3-Bromo-2-[(3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)hydroxymethyl]-7-(1-methylethyl)-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of example 1 part c) following the procedure of example 12, part f) to give the sub-title compound as a solid.

MS (APCI) 489 and 491 $[M+H]^+$

$\delta^1H_{CDCl_3}$ 1.35 (6H, d), 2.35 (3H, s), 2.75 (1H, s), 2.87 (1H, bs), 3.07 (1H, m), 3.80 (3H, s), 6.21 (1H, s), 7.21 (1H, m), 8.78 (2H, m)

b) 3-Bromo-2-[(3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-7-(1-methylethyl)-5-methyl-thieno[2,3-*d*]pyridazin-4(5*H*)-one

Prepared from the product of part a) following the procedure of example 1, part f) to give the sub-title compound as a solid.

MS (ESI) 472 and 474 $[M+H]^+$

$\delta^1H_{CDCl_3}$ 1.28 (6H, d), 2.26 (3H, s), 2.62 (3H, s), 2.94 (1H, m), 3.81 (3H, s), 4.01 (2H, s), 7.19 (1H, m), 7.81 (1H, m), 7.88 (1H, dd), 8.44 (1H, m)

c) 2-[(3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-7-ethyl-4,5-dihydro-5-methyl-4-oxo-thieno[2,3-*d*]pyridazine-3-carboxylic acid

Prepared from the product of part b) following the procedure of example 12, part h) to give the sub-title compound as a solid.

MS (ESI) 438 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.30 (6H, d), 2.23 (3H, s), 2.59 (3H, s), 3.05 (1H, m), 3.94 (3H, s), 4.64 (2H, s), 7.20 (1H, dd), 7.83 (1H, td), 7.91 (1H, d), 8.45 (1H, dd), 16.82 (1H, s)

5 d) 2-[(3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one


Prepared from the product of part c) following the procedure of example 5, part g) to give the title compound as a solid.

10 MS (ESI) 523 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.31 (6H, m), 1.51 (3H, s), 2.27 (3H, s), 2.62 (3H, s), 3.00 (1H, m), 3.44 (1H, d), 3.79 (3H, s), 3.81 (1H, d), 3.97 (1H, d), 4.11 (2H, dd), 4.56 (1H, d), 6.13 (1H, s), 7.18 (1H, t), 7.82 (2H, m), 8.44 (1H, d)

15 Example 16

2-[(3,5-Dimethyl-1-(2-pyrimidinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one



20

Prepared from the product of example 6 (0.9g) and 2-bromopyrimidine (0.64g) in acetonitrile (3mL) heated in a microwave at 130C for 15mins. After evaporation the residue was purified by column chromatography over silica, eluting with ethyl acetate/methanol (20:1) to give the title compound as a solid (0.032 g).

MS (ESI) 524 [M+H]⁺


$\delta^1\text{H}_{\text{CDCl}_3}$ 1.31 (6H, t), 1.52 (3H, s), 2.32 (3H, s), 2.66 (3H, s), 2.97 (1H, m), 3.40 (1H, d), 3.83 (1H, d), 3.98 (1H, d), 4.13 (2H, dd), 4.56 (1H, d), 6.12 (1H, b), 7.19 (1H, t), 8.77 (2H, d)

5

Example 17

2-[(3,5-Dimethyl-1-(2-thiazolyl)-1*H*-pyrazol-4-yl)methyl]-3-[(4*S*)-4-hydroxy-4-methyl-2-isoxazolidinyl]carbonyl-5-methyl-7-(1-methylethyl)thieno[2,3-*d*]pyridazin-4(5*H*)-one

10



Prepared from the product of example 6 (0.222g), 2-bromothiazole (0.222g), copper (1) iodide (0.95g) and trans diaminocyclohexane (0.06mL) mixed under nitrogen. Potassium carbonate (0.222g) and dry dioxan (2mL) were added and the mixture heated at 110C for 3days. After evaporation the residue was purified by column chromatography over silica, eluting with ethyl acetate/ methanol (98:2) then preparative reverse phase HPLC using acetonitrile/aq. ammonia to give the title compound as a solid (0.023g).

15 MS (ESI) 529 [M+H]⁺

$\delta^1\text{H}_{\text{CDCl}_3}$ 1.31 (6H, t), 1.51 (3H, s), 2.25 (3H, s), 2.67 (3H, s), 3.00 (1H, m), 3.41 (1H, d), 3.79 (3H, s), 3.80 (1H, d), 3.97 (1H, d), 4.09 (2H, dd), 4.55 (1H, d), 6.10 (1H, s), 7.06 (1H, d), 7.53 (1H, d)

25

Pharmacological Data**Inhibition of PMA/ionomycin-stimulated peripheral blood mononuclear cell proliferation**

5

The assay for PMA/ionomycin-stimulated PBMC proliferation was performed in 96-well flat-bottomed microtitre plates. Compounds were prepared as 10mM stock solutions in dimethyl sulfoxide. A 50-fold dilution of this was prepared in RPMI and serial dilutions were prepared from this solution. 10 μ l of the 50-fold diluted stock, or 10 dilutions of it, were added to the well to give concentrations in the assay starting at 9.5 μ M and going down. Into each well was placed 1 x 10⁵ PBMC, prepared from human peripheral blood from a single donor, in RPMI1640 medium supplemented with 10% human serum, 2mM glutamine and penicillin/streptomycin. Phorbol myristate acetate (PMA) (0.5ng/ml final concentration) and ionomycin (500ng/ml final concentration) were added to these cells in supplemented RPMI1640 medium (as above) so that the final volume of the assay was 0.2ml. The cells were incubated at 37°C in a humidified atmosphere at 5% carbon dioxide for 72 hours. ³H-Thymidine (0.5 μ Ci) was added for the final 6 hours of the incubation. The level of radioactivity incorporated by the cells was then determined and this is a measure of proliferation.

15

20 The compounds of the Examples were found to exhibit an IA₅₀ value of less than 1 x 10⁻⁶ M in the above test. Examples 3, 7 and 12 had a PIA₅₀ of 8.2, 7.6 and 8.8 respectively in the above test.

Rat Solid Pharmacokinetics (PK) screen**Method**

A Rat Solid PK Screen was carried out according to the method given below for the compounds of Examples 2, 4, 6, 7 and 16 and for the compounds of Examples 8 and 13 of WO 99/29695.

5 1. Dose Preparation

First a solution of the compound to be tested was formed. A standard dose solution of 1 mg ml^{-1} was prepared. Where the compound was not sufficiently soluble in isotonic saline, 50% PEG 400:50% sterile water was used. The required mass of compound was dissolved in the PEG 400 before addition of the water. The concentration of the compound in the dose solution was

10 assayed by diluting an aliquot to a nominal concentration of $50 \mu\text{g/ml}$ and calibrating against duplicate injections of a standard solution and a quality control standard at this concentration.

2. Dosing

The solutions of the compounds were administered intravenously as a bolus into a caudal vein of a rat to groups of three 250-350g rats (approximately 1 ml kg^{-1}). Delivered doses were estimated 15 by weight loss.

3. Sample Collection

Blood samples (0.25ml) were taken from the rats into 1ml syringes, transferred to EDTA tubes and plasma were prepared by centrifugation (3 min at 13000rpm) soon after sample collection.

Sampling times for the standard protocols were at 2, 4, 8, 15, 30, 60, 120, 180 and 240 minutes.

20 4. Sample Analysis

The concentration of the analyte(s) in the plasma was determined quantitatively by mass spectrometry.

4.1 Preparation of Standards and Quality Controls

Standard and quality control (QC) stock solutions were prepared at a concentration $50 \mu\text{g/ml}$ in 25 methanol. The standards and QC stocks were diluted using a TECAN program and spiked into

the plasma according to the following table:

Serial Dilution Program		50 µg/ml stock		
Solution	Volume stock (µl)	Volume Diluent (µl)	Std. Conc. (ng/ml)	QC Conc. (ng/ml)
A	90 of initial stock	810	1000	-
B	300 of A	300	500	500
C	300 of B	300	250	-
D	200 of C	300	100	100
E	300 of D	300	50	-
F	300 of E	300	25	-
G	200 of F	300	10	10
H	300 of G	300	5	-

10µl of each of the above solutions A – H, produced by serial dilution of the combined standard stock, and 10µl of solutions B, D and G, produced by serial dilution of the combined QC stock, 5 were added to 96 well 1.2 ml polypropylene tubes containing 50µl blank plasma by the TECAN. The final concentrations of the standard curve and QC samples produced are shown in the table above.

4.2 Preparation of Samples

To each of the test samples, standards and QCs was added 150 µl of water. The samples were 10 arranged in the order defined below:

1. Standards in order of ascending concentration
2. QCs in order of ascending concentration

3. Manual standard. Test samples from IV dosed animals (1M, 2M and then 3M samples)

The samples were then capped, mixed by repeated inversion and then centrifuged at 3500 rpm in an IEC CENTRA centrifuge for 20 minutes. Aliquots (120 μ l) of each sample were transferred

5 using the TECAN "TFER 120ftalltohp1100" program to HPLC vials ready for analysis.

4.3 Mass Spectrometry

A TSQ700 or a TSQ or SSQ7000 mass spectrometer with a HP1100 HPLC system was used. The sources used were APCI or ESI. A column switching method was used to analyse the direct injection samples with typically a 7 minute re-injection time.

10 HPLC and MS Conditions

Pre-column loading

Solvent A	0.25% Ammonium acetate in H ₂ O
Solvent B	Acetonitrile
Gradient	95%A for 1 min; to 5% over 0.5min, held for 1.5 min
Column	20 x 3.9mm Waters Symmetry Shield C ₈ 3.5 μ M
Flow rate	1 ml/min ⁻¹

Analytical chromatography

Solvent A	0.025% Ammonium acetate in H ₂ O
Solvent B	Acetonitrile
Gradient	40%A for 2 min; to 5% over 2 min, held for 2 min
Column	50 x 3.9mm Waters Symmetry Shield C ₈ 3.5 μ M

Flow rate	1.5 ml/min ⁻¹
Vaporiser heater	550°C
Capillary heater	250°C

Standard and quality control samples covering the range of concentrations found in the test samples were within 25% of the nominal concentration.

5 4.4 Data Analysis

Pharmacokinetic data analysis and tabulation was achieved using WinNonlin and Excell. A standard non-compartmental analysis was used to calculate the Clearance Time (ml/min/kg) and Half Life ($t_{1/2}$) (hour) for each sample tested.

5. Results

	Clearance (ml/min/kg)	Half Life ($t_{1/2}$) hour)
Example 2	40.0	3.73
Example 4	42.3	4.00
Example 6	53.7	3.65
Example 7	38.3	5.50
Example 16	19.3	5.63

WO 99/29695 – comparison results

	Clearance (ml/min/kg)	Half Life ($t_{1/2}$) hour)
Example 8	68.0	0.70
Example 13	64.7	1.03

6. Conclusions

5 The Clearance value is a measure of the potential of a compound to undergo metabolism and it can be used as an index of the relative metabolic stability of compounds. The smaller the Clearance figure obtained for a given compound the greater the potential stability of that compound. The Half Life value, which is linked to the Clearance value is also an indication of the stability of a tested compound the larger the Half Life figure obtained for a given compound
10 the greater the potential stability of that compound.


From the results given above it can be concluded that the compounds of the present invention are more stable than those of WO 99/29695.

As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude
15 other additives, components, integers or steps.

Claims

1. A compound of formula (I):

5



(1)

wherein:

10 R¹ is C₁₋₆ alkyl, C₂₋₆ alkenyl or C₃₋₆ cycloalkyl which is optionally substituted by C₁₋₆ alkyl, each of the above being optionally substituted by one or more halogen atoms;

15 R² is C₁₋₆ alkyl;

20 R³ is a group CO-G or SO₂-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen, and optionally substituted by up to 3 groups selected from hydroxyl and C₁₋₄ alkyl;

25 R⁴ is a 5- to 10-membered mono- or bi-cyclic aromatic ring system, containing 0 to 4 heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by up to 4 groups independently selected from halogen, C₁₋₄ alkyl, (poly)halo-C₁₋₄-alkyl, C₁₋₄ alkoxy, (poly)halo-C₁₋₄-alkoxy, C₁₋₄ alkylsulphonyl, (poly)halo-C₁₋₄-alkylsulphonyl, oxo, thioxo, cyano, hydroxymethyl, methylthio, -NR⁷R⁸, -CO-NR⁷R⁸, -SO₂.NR⁷R⁸, or a 5- to 6-membered aromatic ring system wherein

up to 3 ring atoms may be heteroatoms independently selected from oxygen, sulphur and nitrogen, and which may itself be substituted by up to 4 groups selected from halogen, C₁₋₄ alkyl, (poly)halo-C₁₋₄-alkyl, C₁₋₄ alkoxy, (poly)halo-C₁₋₄-alkoxy, C₁₋₄ alkylsulphonyl, (poly)halo-C₁₋₄-alkylsulphonyl, oxo, thioxo, cyano, hydroxymethyl, 5 methylthio, -NR⁷R⁸, -CO-NR⁷R⁸, -SO₂-NR⁷R⁸;

R⁷ and R⁸ are independently hydrogen, C₁₋₄ alkyl; or R⁷ and R⁸ together with the nitrogen atom to which they are attached may form a 5 to 7 membered saturated heterocyclic ring,

10

or a pharmaceutically acceptable salt or solvate thereof.

15

2. A compound according to claim 1 in which R¹ is C₁₋₆ alkyl or C₃₋₆ cycloalkyl.

20

3. A compound according to claim 1 or 2 in which R² is methyl.

4. A compound according to any one of claims 1 to 3 in which R³ is a group CO-G.


5. A compound according to any one of claims 1 to 4 in which Q is CH₂.

25

6. A compound according to any one of claims 1 to 5 in which R⁴ is a 5-membered aromatic ring containing two heteroatoms optionally substituted as defined in claim 1.

7. A compound according to claim 6 wherein R⁴ is a group of sub-formula (i)

25



where R¹⁰ and R¹¹ are independently selected from H, C₁₋₆alkyl, or haloC₁₋₆alkyl

and R¹² is selected from H, C₁₋₆alkyl, or haloC₁₋₆alkyl or a 5- to 6-membered aromatic ring system wherein up to 3 ring atoms may be heteroatoms independently selected from oxygen, sulphur and nitrogen.

5 8. A compound according to claim 7 wherein R¹⁰ and R¹¹ are methyl.

9. A compound of formula (I) selected from:

2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-2-
isoxazolidinyl]carbonyl]- 5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-
one,
10 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-2-
isoxazolidinyl]carbonyl]- 5-methyl-7-(2-methylpropyl)thieno[2,3-*d*]pyridazin-4(*5H*)-
one,
2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[[*(4S)*-4-hydroxy-2-
15 isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,
7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-2-
isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,
7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-5-ethyl-3-[[*(4S)*-4-hydroxy-2-
isoxazolidinyl]carbonyl]-thieno[2,3-*d*]pyridazin-4(*5H*)-one,
20 2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-5-methyl-7-(1-methylethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one,
2-[(3,5-Dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-thieno[2,3,-*d*]pyridazin-4(*5H*)-
one,
25 2-[(3,5-Dimethyl-1*H*-pyrazol-40yl)methyl]-7-ethyl-3-[[*(4S)*-4-hydroxy-4-methyl-2-
isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,
7-Cyclopropyl-2-[(3,5-dimethyl-1*H*-pyrazol-4-yl)methyl]-3-[[*(4S)*-4-hydroxy-4-methyl-
2-
isoxazolidinyl]carbonyl]-5-methyl-thieno[2,3-*d*]pyridazin-4(*5H*)-one,
30 3-[[*(4S)*-4-hydroxyisoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-2-(1*H*-
pyrrolo[2,3-*b*]pyridine-3-ylmethyl)thieno[2,3,-*d*]pyridazin-4(*5H*)-one,
3-[[*(4S)*-4-Hydroxy-2-isoxazolidinyl]carbonyl]-5-methyl-7-(2-methylpropyl)-2-[(1,3,5-
trimethylpyrazol-4-yl)methyl]-thieno[2,3,-*d*]pyridazin-4(*5H*)-one,

2004205617 13 Jul 2005

2-[(3,5-dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-7-ethyl-3-[(*4S*)-4-hydroxy-2- isoxazolidinyl] carbonyl] -5-methyl-thieno [2, 3-*d*] pyridazin-4 (*5H*)-one,

2-[[3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl]methyl]-7-ethyl-3-[(*4S*)-4-hydroxy-4-methyl-2- isoxazolidinyl] carbonyl]-5-methyl-thieno [2, 3-*d*]pyridazin-4(*5H*)-one,

5 7-Ethyl-3-{[(*4S*)-4-hydroxy-4-methylisoxazolidin-2-yl] carbonyl}-5-methyl-2-(*1H*- pyrrolo [2, 3-*b*] pyridin-3-ylmethyl) thieno [2, 3-*d*]pyridazin-4(*5H*)-one,

2- [(3,5-Dimethyl-1-(2-pyridinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(*4S*)-4-hydroxy-4- methyl-2- isoxazolidinyl] carbonyl-5-methyl-7-(1-methylethyl) thieno [2, 3,-*d*]pyridazin- 4 (*5H*)-one,

2- [(3,5-Dimethyl-1-(2-pyrimidinyl)-1*H*-pyrazol-4-yl)methyl]-3-[(*4S*)-4-hydroxy-4- methyl-2-

10 isoxazolidinyl] carbonyl-5-methyl-7-(1-methylethyl) thieno [2, 3,-*d*]pyridazin- 4 (*5*)-one,

2- [(3,5-Dimethyl-1-(2-thiazolyl)-1*H*-pyrazol-4-yl)methyl]-3-[(*4S*)-4-hydroxy-4-methyl- 2- isoxazolidinyl] carbonyl-5-methyl-7-(1-methylethyl)thieno [2, 3,-*d*]pyridazin-4(*5H*)-one,

or a pharmaceutically acceptable salt thereof.

15 10. A compound according to any one of claims 1 to 9 for use in therapy.

11. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9 in association with a pharmaceutical carrier.

20 12. A method of effecting immunosuppression which comprises administering to a patient a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9.

25 13. A method according to claim 12 wherein the immunosuppression is effected in the treatment of allograft rejection.

14. A method of treating, or reducing the risk of, an airways disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof according to any one of claims 1


30 to 9.

15. A method according to claim 14 wherein the disease is asthma or COPD.

16. A process for the preparation of a compound of formula (I) which comprises:

(a) for compounds of formula (I) where R^3 is COG :

5 reaction of a compound of formula (II):



(II)

10

in which R^1 , R^2 , R^4 and Q are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (III):

G-H


15

(III)

where G is as defined in formula (I) in the presence of a coupling agent, or

(b) for compounds of formula (I) where R^3 is SO_2-G :

20 reacting a compound of formula (IV):



(IV)

in which in which R^1 , R^2 , R^4 and Q are as defined in formula (II) and L and L' are leaving groups with a compound of formula (III) as defined above, and optionally thereafter process (a) or (b) in any order

5 • removing any protecting groups
 • forming a pharmaceutically acceptable salt.

17. A process according to claim 14 which further comprises the step of changing a group of formula R^3 or R^4 in the compound of formula (I) to a different group R^3 or R^4 10 respectively.

18. A compound according to claim 1 substantially as hereinbefore described with reference to any one of the Examples

Dated : 13 July 2005

Freehills Patent & Trade Mark Attorneys
Patent Attorneys for the Applicant/s:

AstraZeneca AB